Core Insights - AstraZeneca announced a $2.5 billion investment in Beijing, which includes establishing a sixth global strategic R&D center and an advanced AI and data science laboratory, highlighting China's role as a global hub for innovative drug development [2] - The number of drugs developed in China has doubled, with approximately one-third of global licensing deals involving Chinese biopharmaceutical companies, indicating China's emergence as a source of innovation [2] - AstraZeneca aims to collaborate with promising Chinese biotech firms to achieve its goal of introducing 20 breakthrough innovative drugs globally by 2030 [2] - In the past two years, AstraZeneca has signed 15 licensing agreements with 14 Chinese biotech companies, showcasing its commitment to leveraging local innovation [2] - AstraZeneca plans to establish around 800 diagnostic and treatment centers in China by the end of 2025 to enhance standardized treatment across various disease areas [3] Company Strategy - AstraZeneca's investment in China is driven by the country's rich clinical research resources and improving innovation capabilities, positioning it as a key hub for global research and clinical development [3] - The company is focused on integrating into China's life sciences ecosystem and is actively seeking collaborations with companies that align with its product portfolio [2] Future Outlook - AstraZeneca is optimistic about the potential for increased foundational research collaboration and innovative therapy exploration in China, aiming to inject stronger momentum into global drug development [3]

AstraZeneca announced plans to change how it lists shares in the United States by moving from American depositary receipts (ADRs) on Nasdaq to a direct listing of its ordinary shares on the New York Stock Exchange. ...

Energy Markets - The global oil market is experiencing significant challenges, with Brent crude prices struggling to remain above $70 per barrel due to a persistent supply glut and subdued global demand [2][8] - The U.S. Energy Information Administration (EIA) forecasts Brent crude prices to decline to an average of $59 per barrel in Q4 2025 and around $51 per barrel in early 2026, driven by large oil inventory builds as OPEC+ increases production by approximately 547,000 barrels per day starting September 2025 [2] - China's liquefied natural gas (LNG) imports are expected to decline for the eleventh consecutive month, with a year-to-date drop of 22% in 2025 and a 30% decrease in the first four months compared to 2024, primarily due to weak industrial demand and increased domestic gas production [3] Currency Movements and Central Bank Actions - The USD/JPY exchange rate has seen a significant drop of 0.6% to 148.61, with the Japanese Yen weakening 1.26% over the past month and 3.64% over the last year, driven by divergent economic performances between the US and Japan [4][8] - The Riksbank in Sweden has cut its policy rate by 0.25 percentage points to 1.75% to stimulate the weak economy, marking the eighth rate reduction since spring last year [5] Corporate Strategies - Verisure, a Switzerland-based security services company, is targeting a valuation of up to €13.9 billion (approximately $16.29 billion) in its planned IPO on Nasdaq Stockholm, aiming to raise €3.1 billion (around $3.7 billion) by selling new shares [6][8] - AstraZeneca plans a direct listing of its ordinary shares on the New York Stock Exchange, maintaining its primary listing in London, to attract a broader global investor base while investing $50 billion in the US over the next five years [7][8] Global Developments - Russia and Vietnam are strengthening energy ties, with new projects expected to begin in January 2026 and a memorandum of understanding signed for cooperation on Vietnam's first nuclear power plant [9] - China's Communist Party will hold its fourth plenary session from October 20 to 23 to deliberate on the 15th Five-Year Plan for National Economic and Social Development, which is closely monitored for its implications on China's economic rebalancing and geopolitical strategy [10]

Group 1 - AstraZeneca plans to list its stock on the New York Stock Exchange to attract more investors while retaining its trading operations in London and its UK headquarters [1] - The new US listing will replace the existing American Depository Receipts (ADRs) [1] - CEO Pascal Soriot has expressed dissatisfaction with the UK regulatory system, fearing that the UK is falling behind the US and China in competitiveness [1] Group 2 - AstraZeneca has faced increasing disappointment from pharmaceutical companies regarding the UK government's efforts to promote the domestic life sciences industry, particularly in areas such as clinical trial numbers and new drug reimbursement policies [1] - Soriot specifically criticized the UK's refusal to promote AstraZeneca's breast cancer drug Enhertu to a broader patient population, highlighting a breakdown in price negotiations [1] - Handelsbanken downgraded AstraZeneca's rating from "Buy" to "Hold," citing concerns that the company's goal of achieving $80 billion in total revenue by 2030 is overly optimistic [2] Group 3 - AstraZeneca has suspended a £200 million (approximately $272.12 million) investment plan at its Cambridge research center, marking a significant reduction in its domestic operations [2] - This decision represents a setback for the UK government as AstraZeneca is the largest publicly listed company in the country [2]

阿斯利康9月29日发布声明称，公司计划协调其股票上市结构，在伦敦证券交易所、斯德哥尔摩证券交 易所和纽约证券交易所为公司普通股上市。这将升级阿斯利康现有的美国股票上市体系，取代现有的美 国存托凭证（ADR）在纳斯达克上市。 阿斯利康表示，公司总部将留在英国。 来源：智通财经 ...

AstraZeneca to List Shares Directly on New York Stock Exchange https://t.co/WNnlQy1BnT ...

(Reuters) -AstraZeneca (AZN) plans to directly list its shares on the New York Stock Exchange, instead of its current depositary receipts structure, to attract more global investors, the drugmaker said on Monday, but will remain listed and headquartered in London. The move will be of some relief to UK investors after media reports suggested the Anglo-Swedish drugmaker - London's most valuable company - was considering ditching its British listing in favour of the U.S. That had raised worries about the shr ...

AstraZeneca said on Monday that it will now directly list its shares on the New York Stock Exchange, instead of the current depository shares, adding that it will continue to be listed and headquarter... ...

Core Viewpoint - The article highlights three pharmaceutical stocks under $100 that are considered attractive investment opportunities: AstraZeneca, Novo Nordisk, and Pfizer. AstraZeneca - AstraZeneca is recognized as a leading healthcare company with significant growth potential, aiming to increase its annual revenue to $80 billion by the end of the decade from $56.5 billion in the last 12 months [5] - The company has a robust pipeline with nearly 200 projects, including over 20 in phase 3 trials, showcasing its commitment to innovation and growth across various therapeutic areas [4][6] - AstraZeneca offers a dividend yield of 2%, which is higher than the S&P 500 average of 1.2%, making it an appealing option for long-term investors [6] Novo Nordisk - Despite recent challenges, including declining sales growth and a downward revision of revenue guidance, Novo Nordisk's stock is viewed as undervalued, trading at just under $59 with a forward price-to-earnings ratio of 14.2, below the industry average of 16.5 [8][9] - The company is expected to benefit from strong growth drivers like Ozempic and Wegovy, with recent label expansions enhancing their market potential [10][11] - Novo Nordisk has several candidates in late-stage studies, positioning it as a leader in the rapidly growing GLP-1 market [11] Pfizer - Pfizer, with a market cap of $135 billion and annual revenue exceeding $60 billion, is considered underrated, trading at only 7.7 times forward earnings and a PEG ratio of 0.96 [12] - The company faces a patent cliff but has promising products in its pipeline, including the multiple myeloma drug Elrexfio, and a total of 108 programs in clinical development [13][14] - Pfizer's forward dividend yield is notably high at 7.24%, providing a strong incentive for investors despite potential challenges in share price appreciation [15]

AstraZeneca PLC (NASDAQ:AZN) ranks among the most undervalued NASDAQ stocks to buy now. Goldman Sachs maintained its Conviction Buy rating on AstraZeneca PLC (NASDAQ:AZN) and boosted its price target from GBP148.83 to GBP150.13 on September 16. The adjustment comes while AstraZeneca PLC (NASDAQ:AZN)  awaits the results of a Phase 3 trial for efzimfotase alfa, an enzyme replacement treatment for hypophosphatasia (HPP). Pixabay/Public Domain Goldman Sachs anticipates these findings soon, pointing out that ...